Small-cap pharmaceutical stocks have sharply outperformed their large-cap peers over the past year, driven by a combination of niche product exposure, China+1 opportunities, improving exports and company-specific growth triggers. Bliss GVS has surged 341% over the last year, while Ind-Swift Laboratories gained 261%, Sakar Healthcare rose 235%, Shilpa Medicare climbed 162% and Kwality Pharma advanced 131%.
In comparison, large-cap pharma stocks have delivered more modest returns. Divis Laboratories gained 55%, Torrent Pharma rose 36% and Sun Pharma advanced 14%. Zydus Lifesciences gained 12%, while Cipla declined 10% during the period. Here are four reasons why the stocks are rallying:
Less Dependence On US Generics
One of the key factors supporting smaller pharma companies is their relatively lower dependence on commoditised US generics.
Large pharmaceutical companies continue to face pricing pressure and intense competition in the US generics market. Several smaller companies, meanwhile, have exposure to niche formulations, specialty products and contract manufacturing, helping them avoid some of the pressure faced by conventional generic businesses.
China+1 Shift Benefits Smaller Players
The global pharmaceutical industry's efforts to diversify supply chains away from China have also created opportunities for Indian small-cap pharma companies.
Small and mid-sized CDMO and CRDMO companies are attracting outsourcing opportunities as global players look to establish alternative manufacturing and development bases.
Focus On High-Margin Niches
Another common theme is a shift towards higher-margin therapeutic segments such as oncology, peptides and complex injectables. These products typically face fewer competitors than conventional generics and can offer better pricing.
Patent expiries in cancer drugs could also create opportunities for Indian manufacturers, while specialty products are allowing companies to grow faster than their traditional generic businesses.
Company-Specific Growth Drivers
Bliss GVS is benefiting from its niche dosage-form portfolio, strong profit growth and a near debt-free balance sheet. Capacity expansion is also supporting its growth.
Ind-Swift Laboratories is pivoting towards high-margin finished-dose exports. CDMO deals with Viatris, Manx and Arrotex are moving into the execution phase, while own-brand exports have risen to 57%, supporting margin expansion.
Shilpa Medicare's focus on oncology APIs, formulations and biologics has supported record revenue and Ebitda. Formulation sales have grown more than 30%, while Ebitda margins have expanded to around 28-29%.
Kwality Pharma is focusing on oncology, injectables and peptides, giving it exposure to higher-margin therapeutic segments.
Sakar Healthcare is seeing growth from oncology exports, new EU launches and a strong dossier approval pipeline. The company expects Ebitda margins to cross 30% by FY27.
What Could Support The Rally?
The CDMO/CRDMO outsourcing pipeline, rupee weakness supporting export realisations, continued demand for oncology, peptides and injectables, and upcoming patent expiries could provide further growth opportunities.
However, the sharp run-up in several small-cap pharma stocks also means company-specific execution, valuations and liquidity will remain important factors for investors to track.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.